Alphatec Holdings, Inc. (ATEC) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Momentum 4.4/10 is below the 5.0 floor at $8.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Invibio (sole-source PEEK supplier); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2).
Alphatec Holdings is a U.S. spine surgery medical device company generating $764.2M revenue in 2025, focused on approach-specific procedural systems (PTP, LTP, ALIF), EOS imaging/surgical planning software, and fixation implants. Revenue is earned through independent sales... Read more
Sell if holding. Momentum 4.4/10 is below the 5.0 floor at $8.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Invibio (sole-source PEEK supplier); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Death cross but MACD improving, RSI 43. Score 5.8/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Alphatec Holdings, Inc.
Material events (past 30 days)
- May 5, 2026 MEDIUM Item 1.02: Prior credit facility terminated and replaced by new $175M term loan A + $125M revolving credit facility with JPMorgan Chase as administrative agent, effective May 1, 2026, maturing May 2031.
Latest news
- Alphatec (NASDAQ:ATEC) Hits New 52-Week Low - Should You Sell? - MarketBeat — MarketBeat negative
- Implied Volatility Surging for Alphatec Stock Options - TradingView — TradingView negative
- Alphatec Holdings Inc expected to post a loss of 2 cents a share - Earnings Preview - TradingView — TradingView negative
- Barclays Maintains Overweight on Alphatec Holdings, Lowers Price Target to $24 — benzinga May 7, 2026 positive
- Wells Fargo Maintains Overweight on Alphatec Holdings, Lowers Price Target to $14 — benzinga May 7, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductpolyaxial pedicle screw systems38%10-K Item 1A: 'Net sales of our systems that include polyaxial pedicle screws represented approximately 38% and 40% our net sales for the years ended December 31, 2025 and 2024'
- HIGHSupplierInvibio (sole-source PEEK supplier)10-K Item 1A: 'We rely on a number of suppliers and in one case on a single source vendor, Invibio, to provide the raw materials'
Material Events(8-K, last 90d)
- 2026-05-05Item 1.02MEDIUMPrior credit facility terminated and replaced by new $175M term loan A + $125M revolving credit facility with JPMorgan Chase as administrative agent, effective May 1, 2026, maturing May 2031.SEC filing →
- 2026-03-03Item 5.02LOWDirector Ward W. Woods retired from the Board effective February 27, 2026 for personal reasons. No disagreement with Company. Board reduced from 8 to 7 directors. Unvested RSUs from June 2025 grant accelerated per Vesting Agreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 4.4/10 is below the 5.0 floor at $8.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Invibio (sole-source PEEK supplier); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2). Chart setup: Death cross but MACD improving, RSI 43. Prior stop was $7.64. Score 5.8/10, moderate confidence.
Take-profit target: $15.08 (+83.5% upside). Prior stop was $7.64. Stop-loss: $7.64.
Concentration risk — Supplier: Invibio (sole-source PEEK supplier); V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Leverage penalty (D/E 33.0): -1.5.
Alphatec Holdings, Inc. trades at a P/E of N/A (forward 14.1). TrendMatrix value score: 9.2/10. Verdict: Sell.
19 analysts cover ATEC with a consensus score of 4.1/5. Average price target: $17.
What does Alphatec Holdings, Inc. do?Alphatec Holdings is a U.S. spine surgery medical device company generating $764.2M revenue in 2025, focused on...
Alphatec Holdings is a U.S. spine surgery medical device company generating $764.2M revenue in 2025, focused on approach-specific procedural systems (PTP, LTP, ALIF), EOS imaging/surgical planning software, and fixation implants. Revenue is earned through independent sales agents and direct reps who sell to hospitals; key products include lateral spine approach systems, SafeOp neuromonitoring, and biologics.